Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultravate Dosing Frequency with Lac-Hydrin in Plaque Psoriasis
NCT00990561Phase 4Completed
- Sponsor
- University of California, San Francisco
- Start
- Jul 2009
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of Halobetasol propionate 0.05% lotion in plaque psoriasis (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Change in Modified Psoriasis Area Severity Index (PASI) Score at 2 weeks. Started Jul 2009; status: completed.
02
Drugs
Halobetasol propionate 0.05% lotion
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00990561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00990561.